The role of complement in transplantation

Molecular Immunology

Volumn 36, Issue 13-14, 1999, Pages 965-971

  Platt, Jeffrey L ^a   Saadi, Soheyla ^a  

^a MAYO CLINIC   (United States)

Author keywords

Allograft; Complement; Complement regulatory proteins; Xenograft

Indexed keywords

ALLOTRANSPLANTATION; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; CONFERENCE PAPER; GRAFT REJECTION; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; TRANSPLANTATION; XENOTRANSPLANTATION;

ACUTE DISEASE; ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; GRAFT REJECTION; HUMANS; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HETEROLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0033368043     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-5890(99)00119-4     Document Type: Conference Paper

References (42)

1. Benzaquen L.R., Nicholson-Weller A., Halperin J.A. Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells. Journal of Experimental Medicine. 179:1994;985-992.
2. Brauer R., Baldwin W., Ibrahim S., Sanfilippo F. The contibution of terminal complement components to acute and hyperacute allograft rejection in the rat. Transplantation. 59:1995;288-293.
3. Brauer R.B., Baldwin W.M. III, Daha M.R., Pruitt S.K., Sanfilippo F. Use of C6-deficient rats to evaluate the mechanism of hyperacute rejection of discordant cardiac xenografts. Journal of Immunology. 151:1993;7240-7248.
4. Bustos M., Coffman T.M., Saadi S., Platt J.L. Modulation of eicosanoid metabolism in endothelial cells in a xenograft model: role of cyclooxygenase-2. Journal of Clinical Investigation. 100:1997;1150-1158.
5. Byrne G.W., McCurry K.R., Martin M.J., McClellan S.M., Platt J.L., Logan J.S. Transgenic pigs expressing human CD59 and decay-accelerating factor produce an intrinsic barrier to complement-mediated damage. Transplantation. 63:1997;149-155.
6. Chapman J., Taylor C., Ting A., Morris P. Immunoglobulin class and specificity of antibodies causing positive T cell crossmatches: relationship to renal transplant outcome. Transplantation. 42:1986;608-613.
7. Chartrand C., O'Regan C., Robitaille P., Pinto-Blonde M. Delayed rejection of cardiac xenografts in C6-deficient rabbits. Immunology. 38:1979;245-248.
8. Collard C.D., Vakeva A., Bukusoglu C., Zund G., Sperati C.J., Colgan S.P., et al. Reoxygenation of hypoxic human umbilical vein endothelial cells activates the classic complement pathway. Circulation. 96:1997;326-333.
9. Cozzi E., Yannoutsos N., Langford G.A., Pino-Chavez G., Wallwork J., White D.J.G. Effect of transgenic expression of human decay-accelerating factor on the inhibition of hyperacute rejection of pig organs. Cooper D.K.C., Kemp E., Platt J.L., White D.J.G. Xenotransplantation: The Transplantation of Organs and Tissues between Species. 1997;665-682 Springer, Berlin.
10. Dalmasso A.P., Platt J.L. Potentiation of C1 inhibitor plus heparin in prevention of complement-mediated activation of endothelial cells in a model of xenograft hyperacute rejection. Transplantation Proceedings. 26:1994;1246-1247.
11. Dalmasso A.P., Vercellotti G.M., Fischel R.J., Bolman R.M., Bach F.H., Platt J.L. Mechanism of complement activation in the hyperacute rejection of porcine organs transplanted into primate recipients. American Journal of Pathology. 140:1992;1157-1166.
12. Dalmasso A.P., Vercellotti G.M., Platt J.L., Bach F.H. Inhibition of complement-mediated endothelial cell cytotoxicity by decay accelerating factor: potential for prevention of xenograft hyperacute rejection. Transplantation. 52:1991;530-533.
13. Davis E.A., Pruitt S.K., Greene P.S., Ibrahim S., Lam T.T., Levin J.L., et al. Inhibition of complement, evoked antibody, and cellular response prevents rejection of pig-to-primate cardiac xenografts. Transplantation. 62:1996;1018-1023.
14. Diamond L.E., McCurry K.R., Oldham E.R., McClellan S.B., Martin M.J., Platt J.L., et al. Characterization of transgenic pigs expressing functionally active human CD59 on cardiac endothelium. Transplantation. 61:1996;1241-1249.
15. Gewurz H., Clark D.S., Cooper M.D., Varco R.L., Good R.A. Effect of cobra venom-induced inhibition of complement activity on allograft and xenograft rejection reactions. Transplantation. 5:1967;1296-1303.
16. Gewurz H., Clark D.S., Finstad J., Kelly W.D., Varco R.L., Good R.A., et al. Role of the complement system in graft rejections in experimental animals and man. Annals of the New York Academy of Sciences. 129:1966;673-713.
17. Hamilton K.K., Hattori R., Esmon C.T., Sims P.J. Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. Journal of Biological Chemistry. 265:1990;3809-3814.
18. Johnston P.S., Wang M.-W., Lim S.M.L., Wright L.J., White D.J.G. Discordant xenograft rejection in an antibody-free model. Transplantation. 54:1992;573-576.
19. Kalady M.F., Lawson J.H., Sorrell R.D., Platt J.L. Decreased fibrinolytic activity in porcine-to-primate cardiac xenotransplantation. Molecular Medicine. 4:1998;629-637.
20. Kaplon R.J., Michler R.E., Xu H., Kwiatkowski P.A., Edwards N.M., Platt J.L. Absence of hyperacute rejection in newborn pig-to-baboon cardiac xenografts. Transplantation. 59:1994;1-6.
21. Kooyman D.L., Byrne G.W., McClellan S., Nielsen D., Tone M., McCurry K.R., et al. In vivo transfer of GPI-linked complement restriction factors from erythrocytes to the endothelium. Science. 269:1995;89-92.
22. McCurry K.R., Kooyman D.L., Alvarado C.G., Cotterell A.H., Martin M.J., Logan J.S., et al. Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury. Nature Medicine. 1:1995;423-427.
23. Mitchison, N., 1954. Passive transfer of transplantation immunity. In: Proceedings of the Royal Society of London, 142, pp. 72-87.
24. Miyagawa S., Hirose H., Shirakura R., Naka Y., Nakata S., Kawashima Y., et al. The mechanism of discordant xenograft rejection. Transplantation. 46:1988;825-830.
25. Morgan B.P. Intervention in the complement system: a therapeutic strategy in inflammation. Biochemical Society Transactions. 24:1995;224-229.
26. Patel R., Terasaki P.I. Significance of the positive crossmatch test in kidney transplantation. New England Journal of Medicine. 280:1969;735-739.
27. Platt J.L. Hyperacute Xenograft Rejection. 1995;R. G. Landes, New York.
28. Platt J.L. Complement Inhibitors. Gallin J.I., Snyderman R., Fearon D.T., Haynes B.F., Nathan C. Inflammation: Basic Principles and Clinical Correlates. 1999;Lippincott-Raven, Philadelphia.
29. Platt J.L., Fischel R.J., Matas A.J., Reif S.A., Bolman R.M., Bach F.H. Immunopathology of hyperacute xenograft rejection in a swine-to-primate model. Transplantation. 52:1991;214-220.
30. Platt J.L., Vercellotti G.M., Dalmasso A.P., Matas A.J., Bolman R.M., Najarian J.S., et al. Transplantation of discordant xenografts: a review of progress. Immunology Today. 11:1990;450-456.
31. Platt J.L., Vercellotti G.M., Lindman B.J., Oegema T.R. Jr, Bach F.H., Dalmasso A.P. Release of heparan sulfate from endothelial cells: implications for the pathogenesis of hyperacute rejection. Journal of Experimental Medicine. 171:1990;1363-1368.
32. Pratt J.R., Hibbs M.J., Laver A.J., Smith R.A.G., Sacks S.H. Effects of complement inhibition with soluble complement receptor-1 on vascular injury and inflammation during renal allograft rejection in the rat. American Journal of Pathology. 149:1996;2055-2066.
33. Rosengard A.M., Cary N.R.B., Langford G.A., Tucker A.W., Wallwork J., White D.J.G. Tissue expression of human complement inhibitor, decay-accelerating factor, in transgenic pigs. Transplantation. 59:1995;1325-1333.
34. Saadi S., Holzknecht R.A., Patte C.P., Stern D.M., Platt J.L. Complement-mediated regulation of tissue factor activity in endothelium. Journal of Experimental Medicine. 182:1995;1807-1814.
35. Saadi S., Ihrcke N.S., Platt J.L. Pathophysiology of xenograft rejection. Lieberman R., Morris R. Principles of Immunomodulatory Drug Development in Transplantation and Autoimmunity. 1996;31-45 Raven Press, New York, NY.
36. Saadi S., Platt J.L. Transient perturbation of endothelial integrity induced by antibodies and complement. Journal of Experimental Medicine. 181:1995;21-31.
37. Saadi S., Platt J.L. Endothelial cell responses to complement activation. Volanakis J.E., Frank M.M. The Human Complement System in Health and Disease. 1998;335-353 Marcel Dekker, Inc, New York.
38. van den Bogaerde J., Aspinall R., Wang M.-W., Cary N., Lim S., Wright L., et al. Induction of long-term survival of hamster heart xenografts in rats. Transplantation. 52:1991;15-20.
39. Weiler J.M., Edens R.E., Linhardt R.J., Kapelanski D.P. Heparin and modified heparin inhibit complement activation in vivo. Journal of Immunology. 148:1991;3210-3215.
40. Weiser M.R., Williams J.P., Moore F.D.J., Kobzik L., Ma M., Hechtman H.B., et al. Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and complement. Journal of Experimental Medicine. 183:1996;2343-2348.
41. Weisman H.F., Bartow T., Leppo M.K., Marsh H.C., Carson G.R., Concino M.F., et al. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science. 249:1990;146-151.
42. Wrenshall L.E., Cerra F.B., Singh R.K., Platt J.L. Heparan sulfate initiates signals in murine macrophages leading to divergent biological outcomes. Journal of Immunology. 154:1995;871-880.